LK
TAK icon

Lumbard & Kellner’s Takeda Pharmaceutical TAK Stock Holding History

Lumbard & Kellner’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-125,744
Closed -$1.96M – 98
2022
Q4 		$1.96M Sell
125,744
-1,202
-0.9% -$16.8K 0.96% 37
2022
Q3 		$1.65M Sell
126,946
-2,651
-2% -$36.9K 0.85% 40
2022
Q2 		$1.82M Sell
129,597
-2,919
-2% -$41.7K 0.93% 41
2022
Q1 		$1.9M Hold
132,516
– – 0.74% 43
2021
Q4 		$1.92M Sell
132,516
-4,177
-3% -$58.6K 0.72% 44
2021
Q3 		$2.24M Sell
136,693
-1,056
-0.8% -$17.7K 0.88% 40
2021
Q2 		$2.32M Buy
137,749
+2,199
+2% +$37.4K 0.9% 35
2021
Q1 		$2.26M Sell
135,550
-828
-0.6% -$14.9K 0.8% 37
2020
Q4 		$2.4M Sell
136,378
-1,052
-0.8% -$18.5K 0.95% 36
2020
Q3 		$2.12M Buy
137,430
+14,645
+12% +$267K 1.04% 34
2020
Q2 		$2.2M Sell
122,785
-5,636
-4% -$101K 1.27% 31
2020
Q1 		$1.95M Sell
128,421
-4,981
-4% -$90.3K 1.31% 30
2019
Q4 		$2.63M Sell
133,402
-402
-0.3% -$7.69K 1.36% 28
2019
Q3 		$2.3M Hold
133,804
– – 1.26% 29
2019
Q2 		$2.37M Sell
133,804
-176
-0.1% -$3.2K 1.27% 27
2019
Q1 		$2.73M Buy
+133,980
New +$2.7M 1.52% 23

Other funds holding TAK

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
MIP
Mondrian Investment Partners London, United Kingdom $6.48B AUM 18.36% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Lumbard & Kellner's TAK Position: Q1 2023 in Review

Lumbard & Kellner sold out of Takeda Pharmaceutical (TAK) in Q1 2023, closing a stake of 125,744 shares — an estimated $1.96M sold.

Lumbard & Kellner first reported a position in TAK in Q1 2019 and held it in 16 quarters. The position peaked at $2.73M in Q1 2019. 300 funds tracked by Wall St. Rank hold TAK as of Q1 2023.

  • Lumbard & Kellner reported no remaining Takeda Pharmaceutical position as of Q1 2023 after selling out during the quarter.
  • Lumbard & Kellner sold 125,744 Takeda Pharmaceutical shares in Q1 2023, an estimated $1.96M.
  • Lumbard & Kellner first reported a position in Takeda Pharmaceutical in Q1 2019 and held it in 16 quarters.
  • Lumbard & Kellner's Takeda Pharmaceutical position peaked at $2.73M in Q1 2019.
  • 300 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q1 2023.

Based on Lumbard & Kellner's 13F filing for Q1 2023, filed 6 Jun 2023.